Aggrastat (tirofiban) / Correvio, Medicure - LARVOL DELTA

Venous thrombolysis combined with Tirofiban in the treatment of capsular warning syndrome: a case report. (PubMed, Am J Transl Res) - "Currently, there is no universally recognized treatment standard. This report presents the experience of treating a CWS patient at our hospital with venous thrombolysis combined with Tirofiban."

Journal • CNS Disorders

Stent-assisted coiling using the pEGASUS-HPC stent for acutely ruptured wide-necked intracranial aneurysms: A multicenter retrospective study. (PubMed, Interv Neuroradiol) - "One patient (4.6%) had transient in-stent thrombosis, which resolved with tirofiban...All three deaths (13.6%) occurred in patients with Hunt and Hess grade V and basilar artery aneurysms.ConclusionThe pEGASUS-HPC stent showed a favorable safety profile with high occlusion and recovery rates in ruptured wide-necked aneurysms. These findings support the use of surface-modified stents in the acute setting and highlight the need for prospective studies to confirm long-term safety and efficacy."

Journal • Retrospective data • Cardiovascular • Hematological Disorders • Subarachnoid Hemorrhage • Thrombosis • Vascular Neurology

Effects of intracoronary tirofiban on no-reflow phenomena in patients with ST-segment elevated myocardial infarction undergoing primary percutaneous coronary intervention (ESC-WCC 2025) - No abstract available

Clinical • Cardiovascular • Myocardial Infarction

Early Tirofiban Infusion after Intravenous Thrombolysis for Stroke. (PubMed, N Engl J Med) - P3 | "In patients with acute ischemic noncardioembolic stroke who underwent thrombolysis within 4.5 hours after onset, early tirofiban increased the likelihood of an excellent functional outcome. The incidence of intracranial hemorrhage was low but higher with tirofiban than placebo. (Funded by the Fundamental Research Funds for Central Universities; ASSET-IT ClinicalTrials.gov number, NCT06134622.)."

Journal • Cardiovascular • Cerebral Hemorrhage • CNS Disorders • Hematological Disorders • Ischemic stroke

Effect of Intravenous Tirofiban Versus Placebo on Excellent Outcome in Patients With Acute Ischemic Stroke: The Multicenter, Randomized INSTANT Trial Protocol. (PubMed, J Am Heart Assoc) - P=N/A | "The INSTANT trial was designed to determine the role of tirofiban within 24 hours after IVT in patients with acute ischemic stroke. Our primary objective is to investigate whether the early administration of tirofiban following IVT can enhance the proportion of patients exhibiting no or minimal symptoms post acute ischemic stroke."

Journal • Atrial Fibrillation • Cardiovascular • Cerebral Hemorrhage • CNS Disorders • Hematological Disorders • Ischemic stroke

Impact of Tirofiban and Cilostazol on Cardiac Recovery in Elderly Patients with Acute Coronary Syndrome. (PubMed, Med Sci Monit) - "Patients were assigned to the control group (n=40), receiving aspirin and clopidogrel, or the observation group (n=40), receiving tirofiban and cilostazol after PCI. Quality-of-life scores improved significantly, and MACE incidence was lower in the observation group. CONCLUSIONS Tirofiban combined with cilostazol enhances cardiac function, reduces inflammation, platelet aggregation, and myocardial injury, and improves prognosis in elderly ACS patients after PCI."

Biomarker • Journal • Acute Coronary Syndrome • Cardiovascular • Inflammation • IL6 • TNFA

ANGEL-DRUG: Endovascular Therapy Combined With Tirofiban for Intracranial Atherosclerotic Acute Ischemic Stroke (clinicaltrials.gov) - P=N/A | N=716 | Not yet recruiting | Sponsor: Beijing Anzhen Hospital

New trial • Atherosclerosis • Cardiovascular • Ischemic stroke

Automated platelet function testing to adjust intravenous anti-platelet therapy (ISTH 2025) - "Methods Samples from 49 mainly neurosurgical patients on antiplatelet therapy with cangrelor or tirofiban were monitored. Routine LTA was performed on a commercially available coagulation analyzer CN-6000 (distributed by Sysmex Corporation and Siemens Healthineers AG) using standard platelet activating reagents (i.e. ADP, Arachidonic Acid, Collagen, Epinephrine, and Ristocetin) in platelet rich plasma (PRP) 140µL each with platelet counts ranging from 30 to 500 G/L...Results In all tested patients the necessary dosage for Kangrelor and Tirofiban could be reduced by up to 75% and up to 50% of the recommended dosing regimen based on regular platelet monitoring without increasing the risk for thromboembolic or bleeding events, respectively, and advantageous reducing therapy expenses - see characteristic platelet function patterns for Kangrelor (Figure 1, A, and C) and Tirofiban (Figure 1, B, and D) in combination with acetylsalicylic acid, respectively. Table or Figure..."

Cardiovascular

Tirofiban induced immune mediated thrombocytopenia in a 75-year-old male undergoing PCI for STEMI (ISTH 2025) - "Patient was subsequently treated with platelet transfusions, high-dose corticosteroids, intravenous immunoglobulin (IVIG), and romiplostim but platelets remained critically low despite continued therapies. The patient was discharged in stable condition with normal platelet counts and resumed dual antiplatelet therapy without complications. Table or Figure Upload"

Acute Coronary Syndrome • Cardiovascular • Chronic Kidney Disease • Diabetes • Diabetic Nephropathy • Hematological Disorders • Hypertension • Immune Thrombocytopenic Purpura • Metabolic Disorders • Nephrology • Renal Disease • Thrombocytopenia • Thrombocytopenic Purpura • Thrombosis

Investigating thrombolytic therapies in a model of embolising coronary microvascular obstruction (ISTH 2025) - "Aims We investigated whether CoFI with concentrated microdoses of alteplase, tenecteplase or tirofiban can induce thrombolysis of human microthrombi in an in vitro microfluidic model of MVO. Repeating a 60-second tirofiban treatment three times with 2-miunte intervals between treatments significantly increased thrombolysis to 40% (p < 0.05). Tirofiban and alteplase combined demonstrated no additional benefit on thrombolysis compared to alteplase alone."

Cardiovascular • Myocardial Infarction

The effectiveness and safety of administering antiplatelet medications following reperfusion therapy in patients with ischemic stroke. (PubMed, Expert Opin Pharmacother) - "Patients were divided into two groups: DAPT (aspirin and clopidogrel) or TAT (aspirin, clopidogrel, and tirofiban). TAT may enhance neurological recovery but increases bleeding risk. Patient selection and monitoring are crucial, and long-term studies are needed to fully evaluate its risk-benefit profile."

Journal • Atherosclerosis • Cardiovascular • Ischemic stroke

Tirofiban Combination Therapy for Acute Ischemic Stroke: A Systematic Review and Meta-Analysis. (PubMed, Brain Behav) - "Tirofiban as an adjunct to standard antiplatelet therapy in AIS patients significantly improves functional outcomes and reduces neurological impairment without increasing the risk of sICH."

Clinical • Journal • Retrospective data • Review • Cardiovascular • Cerebral Hemorrhage • CNS Disorders • Hematological Disorders • Ischemic stroke

Effect of aspiration thrombectomy combined with tirofiban on microvascular obstruction in STEMI patients: a prospective, randomised controlled cardiac magnetic resonance trail (ChiCTR) - P=N/A | N=80 | Not yet recruiting | Sponsor: Changzhou Second People's Hospital; Changzhou Second People's Hospital

New trial • Cardiovascular • Myocardial Infarction

A Clinical Study on the Interventional Clinical Efficacy of Shexiang Baoxin Pills in Patients with STEMI (Qi-Stagnation and Blood-Stasis Syndrome) After PCI. (ChiCTR) - P=N/A | N=80 | Not yet recruiting | Sponsor: Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine; Shuguang Hospital Affiliated to Shanghai University of Traditiona

New trial • Cardiovascular • Fibrosis • Immunology • Myocardial Infarction

Cangrelor in the perioperative management of cardiac surgery: A strategy to minimize risks and optimize outcomes (Euroanaesthesia 2025) - "Tirofiban and oral aspirin were initiated. Its use enabled pseudoaneurysm treatment without compromising antiplatelet management after stenting. VerifyNow confirmed cangrelor's pharmacokinetics and clinical effectiveness.Learning points:• Cangrelor's pharmacokinetics make its use ideal for patients at high risk of bleeding and thrombosis.• VerifyNow allowed precise monitoring of antiplatelet effects.• Oral agents may be less safe than cangrelor in post-stenting cardiac surgery patients."

Surgery • Acute Coronary Syndrome • Cardiovascular • Hematological Disorders • Pain • Thrombosis

Use of 2b/3a inhibitors in patients with stroke due to internal carotid artery oclusion (Euroanaesthesia 2025) - "The duration of infusion was 18-24 hours.After stopping the Aggrastat infusion, patients immediately received loading doses of antiplatelet agents (50% of the cardiological dose): clopidogrel 300 mg, aspirin 150 mg, followed by a transition to dual antiplatelet therapy (Aspirin 100 mg/day indefinitely + Clopidogrel 75 mg/day for 3 months). The use of 2b/3a inhibitors is acceptable for emergency ICA stenting in patients with acute ischemic stroke. The use of Aggrastat is safe and effective, including in combination with systemic thrombolytic drugs. After discontinuation of Aggrastat infusion, it is safe to switch to dual antiplatelet therapy by administering 50% of the cardiac loading dose.Acknowledgements: To the staff of the Department of Anesthesiology and Intensive Care No."

Clinical • Anesthesia • Cardiovascular • Hematological Disorders • Ischemic stroke • Thrombosis • KRAS

Effect of Intracoronary Tirofiban Through Guiding Catheter Compared With Intracoronary Tirofiban Through Aspiration Catheter on the Microvascular Obstruction in Patients With STEMI Undergoing PCI: A Cardiac MR Study. (PubMed, Catheter Cardiovasc Interv) - "Intracoronary tirofiban delivery via aspiration catheter significantly reduces MVO and improves myocardial salvage in STEMI patients undergoing PCI compared to the guiding catheter method, without increasing the risk of bleeding or MACE."

Journal • Cardiovascular • Myocardial Infarction

The efficacy and safety of early Tirofiban adjunctive to endovascular treatment in acute basilar artery occlusive stroke (BASILAR-2) (ChiCTR) - P=N/A | N=378 | Not yet recruiting | Sponsor: The Second Affiliated Hospital of the Army Medical University; Xinqiao Hospital

New trial • Cardiovascular • Ischemic stroke

Tirofiban protects mice against severe RSV pneumonia by potentially inhibiting platelet activation via the GPIbα-vWF pathway. (PubMed, Antiviral Res) - "Notably, tirofiban significantly protected mice from severe pneumonia caused by R96-5. These findings highlight the critical involvement of platelet activation and aggregation in RSV infection and suggest that targeting platelet through the GPIbα-vWF signaling axis may represent a promising therapeutic strategy for severe RSV infection."

Journal • Preclinical • Cardiovascular • Hematological Disorders • Infectious Disease • Pneumonia • Respiratory Diseases • Respiratory Syncytial Virus Infections • Thrombosis

EFFECTS OF TIROFIBAN IN PREVENTING NEUROLOGICAL DETERIORATION IN ACUTE ISCHEMIC STROKE WITH INTRACRANIAL ARTERY STENOSIS (ESOC 2025) - "In patients with severe stenosis or occlusion, tirofiban significantly reduced the incidence of END4 (5.7% vs. 30.8%, adjusted OR 0.156, 95% CI 0.028-0.873, adjusted P=0.034), whereas its effects in preventing END4 were similar to those of aspirin in patients with no stenosis (2.4% vs. 4.6%, adjusted OR 0.193, 95% CI 0.018-2.083, adjusted P=0.175) or mild-to-moderate stenosis (2.9% vs. 10.0%, adjusted OR 0.171, 95% CI 0.015-1.943, adjusted P=0.155). Tirofiban may significantly reduce the incidence of END in patients with severe arterial stenosis or occlusion. Even no statistically significant differences were observed, the clinical significance of tirofiban treatment in these patients warrants further attention and research."

Cardiovascular • Ischemic stroke

TIROFIBAN WITH ENDOVASCULAR TREATMENT FOR ACUTE MILD BASILAR ARTERY OCCLUSION STROKE (ESOC 2025) - "Tirofiban did not improve 90-day functional outcome for patients with acute mild BAO stroke receiving EVT, although it would not increase the risk of sICH and 90-day mortality."

Cardiovascular

INTRACEREBRAL BLEEDING UNDER DUAL ANTIPLATELETS AFTER EMERGENCY RECANALIZATION OF INTRACRANIAL AND EXTRACRANIAL LARGE ARTERY OCCLUSION (ESOC 2025) - "78 patients (35.8%) received early dual antiplatelet agents, i.e. during or timely after ET and before 24 h CT control (ticagrelor in 28, clopidogrel in 46, tirofibane in 3, prasugrel in 1). Clopidogrel/ticagrelor in addition to ASA starting during or timely after intracranial ET and extracranial (stent-protected) PTA in acute stroke patients with extra-intracranial tandem occlusion seems not to be associated with an increased cerebral bleeding risk."

Cardiovascular

INTRAVENOUS TIROFIBAN IN ACUTE ISCHEMIC STROKE PATIENTS NOT RECEIVING REPERFUSION TREATMENTS: A SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS (ESOC 2025) - "Treatment with intravenous tirofiban can be beneficial without increased risk in patients with AIS who are not eligible for reperfusion treatment. Further studies are still needed to validate the generalizability of these findings"

Retrospective data • Review • Cardiovascular • Ischemic stroke

ADVANCING STROKE SAFETY AND EFFICACY THROUGH EARLY TIROFIBAN ADMINISTRATION AFTER INTRAVENOUS THROMBOLYSIS: THE ASSET-IT RANDOMIZED CLINICAL TRIAL (ESOC 2025) - "A total of 832 patients were enrolled between March 14, 2024, and September 25, 2024. The mean (SD) age was xx years, the median [IQR] baseline NIHSS score was xx [yy-zz]. Outcome data collection is complete, and analyses are underway."

Clinical • Late-breaking abstract • Cardiovascular • Ischemic stroke

STROKE ETIOLOGY WAS ASSOCIATED WITH TIROFIBAN EFFICACY IN ACUTE ISCHEMIC STROKE WITHOUT ENDOVASCULAR TREATMENT (ESOC 2025) - "In patients who developed AIS within 24 hours of ictus, intravenous tirofiban was significantly associated with reduced END in the subgroup of patients with large-artery atherosclerosis compared with oral aspirin alone. However, no significant benefit was detected in the small vessel occlusion and undetermined etiology subgroups."

Clinical • Atherosclerosis • Cardiovascular • Ischemic stroke